Biomaterial-Assisted Neoantigen Cancer Vaccine Development Solution

The success of personalized cancer immunotherapy relies not only on the identification of high-quality neoepitopes but also on their precise delivery to the immune system. Creative Biolabs provides a comprehensive, end-to-end biomaterial-assisted neoantigen cancer vaccine development solution designed for preclinical researchers. Our platform integrates advanced material science with multi-omics discovery to overcome traditional delivery hurdles, ensuring robust co-delivery of antigens and adjuvants for maximized antitumor efficacy.

Why Biomaterial-Assisted Delivery is Game-Changing

Overcoming the Delivery Bottleneck

Conventional neoantigen vaccines, such as long peptides or naked mRNA, often suffer from rapid degradation, poor lymphatic drainage, and inefficient uptake by Antigen-Presenting Cells (APCs). Biomaterial platforms—ranging from Lipid Nanoparticles (LNPs) to injectable hydrogels—act as sophisticated vehicles that protect the "payload" and orchestrate the timing and location of the immune response.

Synergistic Co-Delivery Strategy
Our platform emphasizes the simultaneous delivery of neoantigens and immunological adjuvants within a single biomaterial carrier. This ensures that APCs receive both the "danger signal" and the "target signal" at once, triggering potent cross-presentation and CD8+ T cell activation.

Key Scientific Advantages We provide:
Enhanced stability and protection against in vivo enzymatic degradation.
Targeted accumulation in secondary lymphoid organs (Lymph Node targeting).
Controlled release kinetics for long-term immune "memory" induction.
Facilitation of endosomal escape for efficient MHC class I presentation.

Superiority of Biomaterial-Assisted vs. Traditional Formulations

Performance Metric	Traditional Neoantigen Vaccines	Biomaterial-Assisted Platform
Systemic Stability	Very low; half-life measured in minutes.	High; sustained circulation and tissue protection.
Adjuvant Synergy	Diluted in vivo; asynchronous delivery.	Precise spatiotemporal co-delivery to same APC.
MHC Class I Cross-Presentation	Inefficient; requires high dose levels.	Engineered for endosomal escape and MHC-I pathways.
Local Persistence (Depot)	None; rapid clearance from injection site.	Custom hydrogels for local sustained release.

Preclinical Biomaterial-Neoantigen Development Modules

Neoantigen Discovery & Payload Design

Optimizing the starting genetic material or peptide sequences for biomaterial compatibility.

Next-gen sequencing (WES/RNA-seq) & HLA typing for preclinical models.
Bioinformatics ranking tailored to delivery modality (mRNA vs. Peptide).
Structural compatibility analysis for nanoparticle encapsulation.
Antigen engineering for multi-epitope tandem transcript designs.

Custom Formulation & Process Engineering

Sophisticated engineering of nanoparticle and hydrogel delivery systems.

LNP formulation screening via advanced microfluidic mixing.
Development of polymeric nanoparticles for controlled cytosolic release.
Injectable hydrogel depot synthesis for local tumor recurrence prevention.
Biomimetic membrane-coated systems for improved biocompatibility.

Advanced Physical Characterization

Ensuring the structural integrity and stability of the vaccine construct.

Particle size, PDI, and Zeta potential analysis (DLS/Zetasizer).
Encapsulation efficiency (EE%) and payload loading capacity.
Morphology assessment via Cryo-TEM and SEM.
Rheology and injectability profiles for hydrogel platforms.

Functional In Vitro Assessment

Mechanistic validation of cellular uptake and immune activation.

APC uptake kinetics and subcellular localization studies.
Endosomal escape efficiency and cytosolic delivery monitoring.
MHC-I/II presentation and cross-presentation assays.
In vitro T cell priming and cytotoxic activity (IFN-γ ELISpot).

Strategic Preclinical Development Workflow

Integrated Biomaterial-Based Vaccine Workflow

Phase 1 — Project Conceptualization & Strategic Alignment

Selection of tumor indications and sample strategy. We match the candidate neoantigens (mRNA, DNA, or Peptide) with the most suitable biomaterial platform (e.g., LNPs for mRNA, Hydrogels for local sustained peptide release) based on preclinical goals.

Phase 2 — Advanced Synthesis & Payload Loading

Utilizing microfluidics and specialized process engineering to encapsulate neoantigens and adjuvants. This phase focuses on achieving high encapsulation efficiency and the ideal co-delivery ratio for APC activation.

Phase 3 — Physicochemical Analytics & Stability Testing

Rigorous characterization of particle size, distribution, charge, and morphology. We evaluate release kinetics and ensure the formulation remains stable through freezing/thawing or accelerated aging conditions.

Phase 4 — In Vitro & In Vivo Mechanistic Validation

Testing uptake and cross-presentation in cell models, followed by in vivo distribution studies (e.g., Lymph Node targeting). We measure therapeutic durability and tumor regression in syngeneic or humanized mouse models.

Phase 5 — Data Consolidation & Translational Preparation

Generation of comprehensive preclinical data packages, including CMC-oriented analytics and batch consistency reports, providing a streamlined foundation for future development transitions.

Technological Core: High-Potency Delivery Platforms

Microfluidic LNP Engine

Precision mixing technology for Lipid Nanoparticles (LNPs), ensuring uniform size distribution (Low PDI) and high encapsulation for mRNA-based neoantigen vaccines.

Bio-Responsive Hydrogel Depot

Customizable, injectable hydrogels that form a local "immune niche," providing sustained antigen release and adjuvant exposure to prevent post-surgical tumor recurrence.

Translatable Process Support

Integration of Tangential Flow Filtration (TFF) and sterile filtration development into the preclinical workflow to ensure reproducibility and consistency from early-stage screening.

Why Choose Creative Biolabs?

Platform Versatility

Not a one-size-fits-all approach. We offer LNP, lipidoid, polymeric NP, and hydrogel platforms to match your specific neoantigen payload.

Co-Delivery Excellence

Mastery of antigen-adjuvant co-encapsulation ensures maximum spatiotemporal coordination for APC activation.

Integrated Data Logic

We bridge the gap between physical characterization and in vivo efficacy, providing mechanistic insights into vaccine performance.

Pre-Translational Readiness

By focusing on translatable process steps (TFF, Sterile Filtration), we reduce the technical risk of future development transitions.

Research Insight: Strategic Synergies in Neoantigen Immunotherapy

Enhancing anti-CTLA-4 Efficacy via Personalized Vaccines

Recent breakthroughs in preclinical oncology underscore the critical role of vaccine delivery in augmenting the therapeutic success of Immune Checkpoint Inhibitors (ICIs). Research indicates that NCV delivered via optimized platforms can synergize with anti-CTLA-4 to eradicate established tumors in aggressive mouse models.

Dual CD4/CD8 Activation: Biomaterial-assisted vaccines engineered with specific CD4+ epitopes have shown the ability to skew the immune response toward a polyfunctional phenotype, critical for overcoming the tumor's immunosuppressive barrier.
Spatiotemporal Coordination: By synchronizing the exposure of neoantigens and adjuvants, biomaterial platforms ensure that T cells are primed in an environment of high costimulation, effectively mimicking the natural immune response.
Long-term Immunological Memory: Evidence from syngeneic models (MC38/CT26) confirms that sustained delivery via biomaterials leads to a significant increase in switched B cells and memory T cell pools, providing long-term protection against re-challenge.

Therapeutic effect of combined M8 and ICI treatment.

Fig.1 STherapeutic efficacy of M8 combined with immune checkpoint inhibitor (ICI) therapy.^1.2

Preclinical Development FAQs

Depending on the peptide's hydrophobicity and charge, we typically achieve encapsulation efficiencies between 70% and 90% using optimized nanoprecipitation or microfluidic techniques. We provide batch-specific characterization reports to confirm these values.

We utilize Near-Infrared (NIR) fluorescence imaging and IVIS systems to track the accumulation of labeled formulations in the injection site and sentinel lymph nodes. This is critical for confirming that the vaccine reaches the desired APC populations.

Yes. Our injectable hydrogels are engineered with hierarchical pore structures and chemical cross-linkers that allow for the co-loading of payloads with different molecular weights, ensuring synchronized release for superior in situ vaccination effects.

We routinely utilize syngeneic mouse models (e.g., MC38, CT26) where the immune system is fully competent. For testing human-specific neoepitopes, we offer humanized mouse models that express human HLA alleles and T cell receptors.

Absolutely. While our current services are strictly for research use only, we incorporate translatable unit operations such as microfluidic scaling and TFF-based purification to ensure that the preclinical formulation "prototype" is technically viable for later-stage development stages.